Cidara Therapeutics/$CDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cidara Therapeutics
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Ticker
$CDTX
Sector
Primary listing
Employees
38
Headquarters
Website
CDTX Metrics
BasicAdvanced
$2.6B
-
-$10.21
1.19
-
Price and volume
Market cap
$2.6B
Beta
1.19
52-week high
$106.63
52-week low
$10.14
Average daily volume
915K
Financial strength
Current ratio
16.455
Quick ratio
15.856
Long term debt to equity
0.167
Total debt to equity
0.466
Profitability
EBITDA (TTM)
-133.53
Management effectiveness
Return on assets (TTM)
-23.61%
Return on equity (TTM)
-37.05%
Valuation
Price to book
4.73
Price to tangible book (TTM)
4.73
Price to free cash flow (TTM)
-9.089
Free cash flow yield (TTM)
-11.00%
Free cash flow per share (TTM)
-11.221
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-59.32%
3-year earnings per share growth (CAGR)
-21.53%
10-year earnings per share growth (CAGR)
-21.66%
What the Analysts think about CDTX
Analyst ratings (Buy, Hold, Sell) for Cidara Therapeutics stock.
CDTX Financial Performance
Revenues and expenses
CDTX Earnings Performance
Company profitability
CDTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cidara Therapeutics stock?
Cidara Therapeutics (CDTX) has a market cap of $2.6B as of October 06, 2025.
What is the P/E ratio for Cidara Therapeutics stock?
The price to earnings (P/E) ratio for Cidara Therapeutics (CDTX) stock is 0 as of October 06, 2025.
Does Cidara Therapeutics stock pay dividends?
No, Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders as of October 06, 2025.
When is the next Cidara Therapeutics dividend payment date?
Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cidara Therapeutics?
Cidara Therapeutics (CDTX) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.